post-marketing observational study
Showing 1 - 25 of >10,000
Study Assessing Safety and Efficacy of Nerivio for Migraine
Recruiting
- Migraine
- Nerivio
-
Bridgewater, New JerseyTheranica Inc USA
Jul 10, 2023
Brivaracetam:Prospective and Multicentre Post-marketing
Active, not recruiting
- Epilepsy
-
Montréal, Quebec, CanadaCentre Hospitalier de l'Université de Montréal (CHUM)
Jan 18, 2023
ALTUS Powered Stapler Used in Bariatric Surgery
Not yet recruiting
- Obesity
- Stapler
-
São Paulo, SP, BrazilHospital IGESP
Nov 29, 2022
Subcutaneous Infusion of ABBV-951 to Assess Change in Disease
Not yet recruiting
- Parkinson's Disease (PD)
- (no location specified)
Jun 15, 2023
Adult Diabetic Macular Edema and Suboptimal Response to
Not yet recruiting
- Diabetic Macular Edema
- (no location specified)
Jul 31, 2023
Fibryga in Congenital Fibrinogen Deficiency
Recruiting
- Congenital Fibrinogen Deficiency
- Fibryga
-
Frankfurt, Germany
- +1 more
Jan 31, 2023
The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks Trial (Verzenios)
Not yet recruiting
- The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks
- Verzenios
- (no location specified)
Mar 3, 2022
Oral Nutritional Supplement in Type 2 Diabetes or at Risk of
Not yet recruiting
- Malnutrition
- Diabetes
- Oral Nutritional Supplement (ONS)
- (no location specified)
Jun 21, 2023
Oral Upadacitinib Tablets to Assess Adverse Events and Change in
Not yet recruiting
- Atopic Dermatitis (AD)
- (no location specified)
Jul 17, 2023
Confirm the Safety and Efficacy of MARVELON (Study P06083)
Completed
- Contraception
- Ethinylestradiol + Desogestrel
- (no location specified)
Feb 2, 2022
Elonva (Corifollitropin Alfa) in General Practice (P08165)
Completed
- Infertility, Female
- corifollitropin alfa
- (no location specified)
Feb 1, 2022
EU Secondary Data Post-Authorisation Safety Study of AZD1222
Recruiting
- COVID-19, Vaccine Adverse Events of Special Interest
- AZD1222
-
Firenze, Italy
- +4 more
Jan 9, 2023
Disease Activity and Adverse Events of Adalimumab in Chinese
Recruiting
- Polyarticular Juvenile Idiopathic Arthritis
-
Wuhan, Hubei, China
- +1 more
Nov 30, 2022
Remitoro in Recurrent or Refractory Peripheral T Cell Lymphoma
Recruiting
- Lymphoma, T-cell, Peripheral
- Lymphoma, T-cell, Cutaneous
-
Nagoya, Japan
- +2 more
Nov 24, 2022
STEMI - ST Elevation Myocardial Infarction, Anterior MI Trial in Dresden (PiCSO)
Not yet recruiting
- STEMI - ST Elevation Myocardial Infarction
- Anterior MI
- PiCSO
-
Dresden, GermanyHerzzentrum Dresden GmbH Universitätsklinik an der TU Dresden
Aug 23, 2022
Von Willebrand Disease Trial (Alphanate SD/HT)
Active, not recruiting
- Von Willebrand Disease
- Alphanate SD/HT
- (no location specified)
May 5, 2022
Moxetumomab Pasudotox-tdfk (LUMOXITI)
Recruiting
- Hairy Cell Leukemia
-
Pueblo, Colorado
- +1 more
Aug 17, 2022
A 52-week Post-marketing, Observational Study to Confirm Safety
Completed
- Hypercholesterolemia
- +2 more
- Ezetimibe
- Ezetimibe + other lipid-lowering medication(s)
- (no location specified)
Feb 7, 2022
A 12-week Post-marketing, Observational Study to Confirm Safety
Completed
- Hypercholesterolemia
- +2 more
- Ezetimibe
- Ezetimibe + other lipid-lowering medication(s)
- (no location specified)
Feb 7, 2022
Nagor Perle Mammary Implants
Not yet recruiting
- Breast Reconstruction
- +7 more
- PERLE Sterile Smooth Opaque gel filled mammary implants
- (no location specified)
Aug 22, 2023
(Special Use-results Surveillance on Long-term Use) With
Enrolling by invitation
- Adult Growth Hormone Deficiency
-
Fukuoka, Japan
- +6 more
Nov 8, 2022